Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19

Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19

Saved in:

Bibliographic Details
Main Author:	Mehmet Agirbasli
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-02-01
Series:	Future Science OA
Subjects:	anticoagulation COVID-19 fibrosis
Online Access:	https://www.future-science.com/doi/10.2144/fsoa-2021-0127
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Management of Pulmonary Fibrosis in COVID-19
by: Cleopas Martin Rumende, et al.
Published: (2021-07-01)

Subtotal Thrombosis of the Left Pulmonary Artery Trunk as a Complication of COVID-19: a Clinical Case
by: T. I. Kalenchits, et al.
Published: (2024-03-01)

Lung Fibrosis Sequelae After Recovery from COVID-19 Infection
by: Agus Dwi Susanto, et al.
Published: (2021-03-01)

Factors affecting the development of liver fibrosis in patients who experienced COVID-19
by: M. V. Kruchinina, et al.
Published: (2023-07-01)

Resolution of the International meeting of experts on the exchange of scientific experience in the use of anticoagulants in patients with COVID-19
by: S. N. Avdeev, et al.
Published: (2020-09-01)

Pulmonary Fibrosis Caused by Severe COVID-19 Infection: Discharge May Not Be The End of Treatment
by: Cleopas Martin Rumende
Published: (2021-07-01)

A review of COVID-19-related thrombosis and anticoagulation strategies specific to the Asian population
by: Kai Chin Poh, et al.
Published: (2022-07-01)

The effect of oral anticoagulant use before visit for patients with COVID-19 on mortality: A meta-analysis
by: Cornelia Ghea, et al.
Published: (2023-01-01)

MODERN ASPECTS OF COAGULOPATHY DEVELOPMENT IN PATIENTS WITH COVID-19 INFECTION: LITERATURE REVIEW
by: M.O. Dudchenko, et al.
Published: (2021-12-01)

COVID-19: a vascular nightmare unfolding
by: Qinan Yin, et al.
Published: (2025-08-01)

Efficacy and Safety of Oral Anticoagulants in the Treatment of COVID-19
by: O. G. Ni, et al.
Published: (2021-07-01)

The Challenging Anticoagulant Therapy in Patient with COVID-19-Associated Coagulopathy
by: Raissa Virgy Rianda, et al.
Published: (2021-10-01)

Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients: A Systematic Review and Meta-Analysis
by: Rahajeng N Tunjungputri, et al.
Published: (2022-07-01)

Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
by: Hitesh Taleja, et al.
Published: (2021-09-01)

Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients
by: Shaaf Ahmad, et al.
Published: (2025-01-01)

Fibrosis of the cardiovascular and respiratory systems after suffering COVID-19: the contribution of immune system factors and genetic predisposition
by: A. S. Golovkin, et al.
Published: (2020-11-01)

Inpatient rehabilitation for a patient with COVID-19 exacerbation of pulmonary fibrosis: a case report
by: Heather McKenna, et al.
Published: (2025-03-01)

Diabetes mellitus increases the risk of post-COVID-19 pulmonary fibrosis: a meta-analysis of observational studies
by: Fen Tan, et al.
Published: (2025-08-01)

COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru
by: Yeisson Rivero-Moreno, et al.
Published: (2025-03-01)

New Insights on Post-COVID-19 Pulmonary Fibrosis: Risk Factors and Clinical Correlations
by: Nasir Abdelrafie, et al.
Published: (2024-12-01)

Surviving COVID-19 and Battling Fibrosis: A Retrospective Cohort Study Across Three Pandemic Waves
by: Mihai Lazar, et al.
Published: (2024-12-01)

The effectiveness and safety of the use of antithrombotic therapy in COVID-19
by: K. V. Lobastov, et al.
Published: (2021-11-01)

Prolonged course of novel coronavirus infection COVID-19 with the formation of pulmonary fibrosis in an HIV-infected patient
by: M. A. Savchenko, et al.
Published: (2024-04-01)

ASSOCIATION BETWEEN HEPARIN DOSE AND 6-WEEKS MORTALITY IN PATIENTS WITH COVID-19
by: Claire Coutureau, et al.
Published: (2022-04-01)

COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention
by: K. V. Lobastov, et al.
Published: (2021-01-01)

Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID‐19: An Analysis of the American Heart Association COVID‐19 Cardiovascular Disease Registry
by: Mathew S. Lopes, et al.
Published: (2025-03-01)

Transcriptomic analysis reveals shared deregulated neutrophil responses in COVID-19 and idiopathic pulmonary fibrosis
by: Georgios Divolis, et al.
Published: (2025-06-01)

nticoagulant therapy monitoring in COVID-19 patients in the intensive care unit: thromboelastometry and echocardiography
by: Yu. L. Ketsko, et al.
Published: (2022-02-01)

Inflammatory, fibrotic and endothelial biomarker profiles in COVID-19 patients during and following hospitalization
by: Fares Darawshy, et al.
Published: (2025-07-01)

Acute aortic occlusion associated with COVID‐19: A rare complication of a not so rare disease
by: Ryan Lee, et al.
Published: (2022-06-01)

COVID-19 knowledge, attitude, and practice in combating TB and COVID-19 in Cameroon
by: Genevieve Andoseh, et al.
Published: (2025-05-01)

Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia?
by: P. A. Davtyan, et al.
Published: (2022-02-01)

Identifying central symptom clusters and correlates among post-COVID-19 pulmonary fibrosis patients: a network analysis
by: Zhen Yang, et al.
Published: (2025-05-01)

Can the golden nutraceutical frankincense combat COVID‐19?
by: Hidayat Hussain
Published: (2024-03-01)

The Intricate Relationship Between Pulmonary Fibrosis and Thrombotic Pathology: A Narrative Review
by: Giovanni Cenerini, et al.
Published: (2024-12-01)

Analysis of expression profile of long non-coding RNA in patients with idiopathic and COVID-19-induced pulmonary fibrosis
by: G. F. Korytina, et al.
Published: (2023-12-01)

Beneficio terapéutico plausible de CIMAvax-EGF® en pacientes con trastornos respiratorios pos-COVID-19
by: Héctor José Pérez Hernández
Published: (2024-04-01)

Healthcare transition readiness of families of youth with cystic fibrosis during COVID-19: A correlational multicenter analysis
by: Tyra C. Girdwood, et al.
Published: (2024-01-01)

Serologically assessed markers of fibroblast activity (PRO-C3 and PRO-C6) and risk assessment of pulmonary fibrosis following severe COVID-19 infection
by: Anne Orholm Nielsen, et al.
Published: (2025-12-01)

Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial
by: Fei Jing, et al.
Published: (2025-03-01)